Metabolic alterations in cancers can be exploited for diagnostic, prognostic, and therapeutic purposes. This is exemplified by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (FDG-PET), an imaging tool that relies on enhanced glucose uptake by tumors for diagnosis and staging. By performing transcriptomic analysis of breast cancer (BC) samples from patients stratified by FDG-PET, a 54-gene signature (PETsign) is identified that recapitulates FDG uptake. PETsign is independently prognostic of clinical outcome in luminal BCs, the most common and heterogeneous BC molecular subtype, which requires improved stratification criteria to guide therapeutic decision-making. The prognostic power of PETsign is stable across independent BC cohorts and disease stages including the earliest BC stage, arguing that PETsign is an ab initio metabolic signature. Transcriptomic and metabolomic analysis of BC cells reveals that PETsign predicts enhanced glycolytic dependence and reduced reliance on fatty acid oxidation. Moreover, coamplification of PETsign genes occurs frequently in BC arguing for their causal role in pathogenesis. CXCL8 and EGFR signaling pathways feature strongly in PETsign, and their activation in BC cells causes a shift toward a glycolytic phenotype. Thus, PETsign serves as a molecular surrogate for FDG-PET that could inform clinical management strategies for BC patients.A molecular signature, PETsign, is derived from breast cancer (BC) patients stratified by - positron emission tomography. PETsign recapitulates the metabolic activity of BCs and is an independent predictor of disease outcome. C-X-C motif chemokine ligand 8 (CXCL8) and epidermal growth factor receptor (EGFR) signaling pathways are prominent in PETsign, and their activation in BC cells causes a shift toward a glycolytic phenotype. image

A PET-Surrogate Signature for the Interrogation of the Metabolic Status of Breast Cancers

Pennisi, Rosa
Co-first
;
Martino, Flavia;Ceci, Francesco;Lanzetti, Letizia
Co-last
2024-01-01

Abstract

Metabolic alterations in cancers can be exploited for diagnostic, prognostic, and therapeutic purposes. This is exemplified by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (FDG-PET), an imaging tool that relies on enhanced glucose uptake by tumors for diagnosis and staging. By performing transcriptomic analysis of breast cancer (BC) samples from patients stratified by FDG-PET, a 54-gene signature (PETsign) is identified that recapitulates FDG uptake. PETsign is independently prognostic of clinical outcome in luminal BCs, the most common and heterogeneous BC molecular subtype, which requires improved stratification criteria to guide therapeutic decision-making. The prognostic power of PETsign is stable across independent BC cohorts and disease stages including the earliest BC stage, arguing that PETsign is an ab initio metabolic signature. Transcriptomic and metabolomic analysis of BC cells reveals that PETsign predicts enhanced glycolytic dependence and reduced reliance on fatty acid oxidation. Moreover, coamplification of PETsign genes occurs frequently in BC arguing for their causal role in pathogenesis. CXCL8 and EGFR signaling pathways feature strongly in PETsign, and their activation in BC cells causes a shift toward a glycolytic phenotype. Thus, PETsign serves as a molecular surrogate for FDG-PET that could inform clinical management strategies for BC patients.A molecular signature, PETsign, is derived from breast cancer (BC) patients stratified by - positron emission tomography. PETsign recapitulates the metabolic activity of BCs and is an independent predictor of disease outcome. C-X-C motif chemokine ligand 8 (CXCL8) and epidermal growth factor receptor (EGFR) signaling pathways are prominent in PETsign, and their activation in BC cells causes a shift toward a glycolytic phenotype. image
2024
1
14
https://onlinelibrary.wiley.com/doi/10.1002/advs.202308255
FDG‐PET; breast cancer; gene signature; glycolysis; metabolism
Confalonieri, Stefano; Matoskova, Bronislava; Pennisi, Rosa; Martino, Flavia; De Mario, Agnese; Miloro, Giorgia; Montani, Francesca; Rotta, Luca; Ferr...espandi
File in questo prodotto:
File Dimensione Formato  
Advanced Science2024.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 3.09 MB
Formato Adobe PDF
3.09 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1986313
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact